Tauriga Sciences, Inc. Establishes Two Additional UPC Category Classifications for its Flagship Brand Tauri-Gum


These Additional Classifications are: Tauri-Gum™ Cases (8 Retail Boxes) & Tauri-Gum™ Shipment Crates (48 Retail Boxes)

These Additional Classifications are: Tauri-Gum™ Cases (8 Retail Boxes) & Tauri-Gum™ Shipment Crates (48 Retail Boxes)

These Additional Classifications are: Tauri-Gum™ Cases (8 Retail Boxes) & Tauri-Gum™ Shipment Crates (48 Retail Boxes)

NEW YORK, NY, Feb. 08, 2021 (GLOBE NEWSWIRE) — via NewMediaWire — Tauriga Sciences, Inc. (OTCQB: TAUG) (“Tauriga” or the “Company”), a revenue generating, diversified life sciences company, with a proprietary line of CBD & CBG infused Supplement chewing gums (Flavors: Pomegranate, Blood Orange, Peach-Lemon, Pear Bellini, Mint, Black Currant) as well as an ongoing Pharmaceutical Development initiative, today announced that it has established two additional Universal Product Code (“UPC”) category classifications for its flagship brand Tauri-Gum™.  These additional classifications are: Tauri-Gum™ Cases (8 Retail Boxes) and Tauri-Gum™ Shipment Crates (48 Retail Boxes).  Previously the Company had only secured UPCs, for the Individual Tauri-Gum™ Blister Pack and the Individual Tauri-Gum™ Retail Box.  These additional UPC category classifications were secured in preparation for sizable wholesale orders and in anticipation of future demand from large retailers. 

UPC Barcodes Categories for Tauri-Gum™ Product Line:

A.   Blister Pack (8 pieces of chewing gum)

B.   Retail Box (10 blister packs)

C.   Case (8 Retail Boxes)

D.   Shipment Crate (48 Retail Boxes)

In other news, the Company is reporting meaningful progress with respect to the ongoing development of its Cannabinoid-Based Pharmaceutical Grade Chewing Gum.  The Company expects to provide shareholders with a material update, within the near term.  

The Company’s proposed “Anti-Nausea” Cannabinoid-Based Pharmaceutical Grade Chewing Gum candidate is being developed specifically to target: Patients Subjected to Ongoing Chemotherapy Treatment (the “Indication”).  

On March 18, 2020, the Company announced that it had filed a Provisional U.S. Patent covering its proposed Pharmaceutical Grade version of Tauri-Gum™. This patent application, filed with the United States Patent & Trademark Office (“U.S.P.T.O.”), is titled: “MEDICATED CBD COMPOSITIONS, METHODS OF MANUFACTURING, AND METHODS OF TREATMENT.”
U.S. Provisional Patent Application No. 62/990,709


Tauriga Sciences, Inc. (TAUG) is a revenue generating, diversified life sciences company, engaged in several major business activities and initiatives.  The company manufactures and distributes several proprietary retail products and product lines, mainly focused on the Cannabidiol (“CBD”) and Cannabigerol (“CBG”) Edibles market segment.  The main product line, branded as Tauri-Gum™, consists of a proprietary supplement chewing gum that is Kosher certified, Halal certified, and Vegan Formulated (CBD Infused Tauri-Gum™ Flavors: Mint, Blood Orange, Pomegranate), (CBG Infused Tauri-Gum™ Flavors: Peach-Lemon, Black Currant) & (Vitamin C + Zinc “Immune Booster” Flavor: Pear Bellini).  The Company’s commercialization strategy consists of a broad array of retail customers, distributors, and a fast-growing E-Commerce business segment (E-Commerce website: www.taurigum.com). Please visit our corporate website, for additional information, as well as inquiries, at http://www.tauriga.com.

Complementary to the Company’s retail business, is its ongoing Pharmaceutical Development initiative.  This relates to the development of a proposed Pharmaceutical grade version of Tauri-Gum™, for nausea regulation (specifically designed for the following indication: Patients Subjected to Ongoing Chemotherapy Treatment). On March 18, 2020, the Company announced that it had filed a provisional U.S. patent application covering its pharmaceutical grade version of Tauri-Gum™.  The Patent, filed with the U.S.P.T.O. is Titled “MEDICATED CBD COMPOSITIONS, METHODS OF MANUFACTURING, AND METHODS OF TREATMENT”.  On December 18, 2020 the Company disclosed that it had entered into a Master Services Agreement with CSTI to lead the Company’s clinical development efforts.

On October 6, 2020, the Company announced that it has been approved to operate as a U.S. Government Vendor (CAGE CODE # 8QXV4)

The Company is headquartered in Wappingers Falls, New York. In addition, the Company operates a full time E-Commerce fulfillment center located in LaGrangeville, New York.

DISCLAIMER — Forward-Looking Statements

This press release contains certain “forward-looking statements” as defined by the Private Securities Litigation Reform Act of 1995 which represent management’s beliefs and assumptions concerning future events. These forward-looking statements are often indicated by using words such as “may,” “will,” “expects,” “anticipates,” believes, “hopes,” “believes,” or plans, and may include statements regarding corporate objectives as well as the attainment of certain corporate goals and milestones. Forward-looking statements are based on present circumstances and on management’s present beliefs with respect to events that have not occurred, that may not occur, or that may occur with different consequences or timing than those now assumed or anticipated. Actual results may differ materially from those expressed in forward-looking statements due to known and unknown risks and uncertainties, such as are not guarantees of general economic and business conditions, the ability to successfully develop and market products, consumer and business consumption habits, the ability to consummate successful acquisition and licensing transactions, fluctuations in exchange rates, and other factors over which Tauriga has little or no control. Many of these risks and uncertainties are discussed in greater detail in the “Risk Factors” section of Tauriga’s Form 10-K and other filings made from time to time with the Securities and Exchange Commission. Such forward-looking statements are made only as of the date of this release, and Tauriga assumes no obligation to update forward-looking statements to reflect subsequent events or circumstances. You should not place undue reliance on these forward-looking statements.


Tauriga Sciences, Inc.
4 Nancy Court, Suite 4
Wappingers Falls, NY 12590
Chief Executive Officer
Mr. Seth M. Shaw
Email:  sshaw@tauriga.com
Cell # (917) 796 9926
Company Instagram: @taurigum
Personal Instagram: @sethsms47
Twitter: @SethMShaw
Corp. Website: www.tauriga.com 
E-Commerce Website: www.taurigum.com



error: Content is protected !!